Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/34684
Title: Letter: Comparing first-line infliximab and vedolizumab for ulcerative colitis-it depends on how you use the drug.
Austin Authors: Con, Danny;Srinivasan, Ashish 
Affiliation: Gastroenterology and Hepatology
Department of Medicine, Faculty of Medicine, Dentistry & Health Sciences, The University of Melbourne, Melbourne, Australia.
Issue Date: Jan-2024
Publication information: Alimentary Pharmacology & Therapeutics 2024-01; 59(1)
URI: https://ahro.austin.org.au/austinjspui/handle/1/34684
DOI: 10.1111/apt.17770
ORCID: 0000-0002-4983-6103
Journal: Alimentary Pharmacology & Therapeutics
Start page: 140
End page: 141
PubMed URL: 38085945
ISSN: 1365-2036
Type: Journal Article
Subjects: Infliximab/therapeutic use
Colitis, Ulcerative/diagnosis
Colitis, Ulcerative/drug therapy
Antibodies, Monoclonal, Humanized/therapeutic use
Appears in Collections:Journal articles

Show full item record

Page view(s)

14
checked on Oct 9, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.